Drug Profile

SCTB 35

Alternative Names: SCTB-35

Latest Information Update: 26 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sinocelltech
Class Antineoplastics; Bispecific antibodies; Immunoglobulin fragments; Immunotherapies; Recombinant fusion proteins
Mechanism of Action Cytotoxic T lymphocyte stimulants; Immunologic cytotoxicity

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

09 Jun 2026 Phase-III clinical trials in Follicular lymphoma (Combination therapy, Second-line therapy or greater) in China (SC) (NCT07562022)
04 Jun 2026 Phase-III clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, Combination therapy) in China (SC) (NCT07570823)
06 May 2026 Sinocelltech plans a phase III trial for Diffuse large B cell lymphoma (Combination therapy, Second-line therapy or greater) in China (SC), in May 2026 (NCT07570823)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com